Login Register Cart 0
Systematic Review Article

金属蛋白酶-1抑制剂在非小细胞肺癌中的预后影响：系统评价和Meta分析

卷 26, 期 42, 2019

页: [7694 - 7713] 页: 20

弟呕挨: 10.2174/0929867325666180904114455

价格: $65

摘要

背景与目的：金属蛋白酶1（TIMP-1）的组织抑制剂是一种多功能的天然基质素抑制剂，通常被认为是癌症转移的负调节剂。报告TIMP-1在非小细胞肺癌（NSCLC）中的预后价值的临床研究不一致。因此，本研究旨在确定TIMP-1表达在NSCLC中的预后影响。 方法：截止至2018年3月7日，在中国国家知识基础设施（CNKI），Cochrane图书馆，PubMed和Web of Science数据库中进行了适当的全文检索研究。汇总的整体生存风险比（HR）以95％置信区间（95％CI）评估TIMP-1的表达与NSCLC患者生存之间的关系。 结果：荟萃分析包括40项研究，包括3194例患者。研究结果表明，TIMP-1的高表达与总体生存不良（HR：1.60； 95％CI：1.50、1.69； P <0.00001）独立，且异质性为61％。此外，我们分析了亚组，包括种族，组织学类型，TIMP-1表达水平的百分比，标本和肿瘤分期。所有结果均具有统计学意义。我们的Meta分析结果表明，TIMP-1的高表达水平与NSCLC患者的不良预后相关。 结论：TIMP-1的表达水平除了可能作为治疗目标外，还代表NSCLC患者的潜在预后生物标志物。

关键词: 抗凋亡，细胞增殖，IHC，meta分析，非小细胞肺癌，肿瘤侵袭，金属蛋白酶-1的组织抑制剂。

« Previous Next »
[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin., 2017, 67(1), 7-30.
[http://dx.doi.org/10.3322/caac.21387] [PMID: 28055103]
[2]
Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China, 2015. CA Cancer J. Clin., 2016, 66(2), 115-132.
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[3]
Petersen, I.; Warth, A. Lung cancer: developments, concepts, and specific aspects of the new WHO classification. J. Cancer Res. Clin. Oncol., 2016, 142(5), 895-904.
[http://dx.doi.org/10.1007/s00432-015-2004-4] [PMID: 26197868]
[4]
Zhang, H.; Guttikonda, S.; Roberts, L.; Uziel, T.; Semizarov, D.; Elmore, S.W.; Leverson, J.D.; Lam, L.T. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene, 2011, 30(16), 1963-1968.
[http://dx.doi.org/10.1038/onc.2010.559] [PMID: 21132008]
[5]
Spurr, N.K.; Goodfellow, P.N.; Docherty, A.J. Chromosomal assignment of the gene encoding the human tissue inhibitor of metalloproteinases to Xp11.1-p11.4. Ann. Hum. Genet., 1987, 51(3), 189-194.
[http://dx.doi.org/10.1111/j.1469-1809.1987.tb00870.x] [PMID: 3688834]
[6]
Shen, W.; Zhu, J.; Yu, Z.; Xue, Q. [TIMP-1 secreted by fibroblasts inhibits tumor cell invasion and metastasis in mouse melanoma] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2009, 26(3), 610-614.
[PMID: 19634683]
[7]
Bourboulia, D.; Stetler-Stevenson, W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol., 2010, 20(3), 161-168.
[http://dx.doi.org/10.1016/j.semcancer.2010.05.002] [PMID: 20470890]
[8]
Brew, K.; Nagase, H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta, 2010, 1803(1), 55-71.
[http://dx.doi.org/10.1016/j.bbamcr.2010.01.003] [PMID: 20080133]
[9]
Wang, N.; Zhu, M.; Tsao, S.W.; Man, K.; Zhang, Z.; Feng, Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma. PLoS One, 2012, 7(9) e46318
[http://dx.doi.org/10.1371/journal.pone.0046318] [PMID: 23029478]
[10]
Jee, B.K.; Park, K.M.; Surendran, S.; Lee, W.K.; Han, C.W.; Kim, Y.S.; Lim, Y. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Biochem. Biophys. Res. Commun., 2006, 342(2), 655-661.
[http://dx.doi.org/10.1016/j.bbrc.2006.01.153] [PMID: 16488391]
[11]
Würtz, S.O.; Schrohl, A.S.; Sørensen, N.M.; Lademann, U.; Christensen, I.J.; Mouridsen, H.; Brünner, N. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr. Relat. Cancer, 2005, 12(2), 215-227.
[http://dx.doi.org/10.1677/erc.1.00719] [PMID: 15947098]
[12]
Chirco, R.; Liu, X.W.; Jung, K.K.; Kim, H.R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev., 2006, 25(1), 99-113.
[http://dx.doi.org/10.1007/s10555-006-7893-x] [PMID: 16680576]
[13]
Kopitz, C.; Gerg, M.; Bandapalli, O.R.; Ister, D.; Pennington, C.J.; Hauser, S.; Flechsig, C.; Krell, H.W.; Antolovic, D.; Brew, K.; Nagase, H.; Stangl, M.; von Weyhern, C.W.; Brücher, B.L.D.M.; Brand, K.; Coussens, L.M.; Edwards, D.R.; Krüger, A. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res., 2007, 67(18), 8615-8623.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-0232] [PMID: 17875701]
[14]
Ivaska, J.; Pallari, H.M.; Nevo, J.; Eriksson, J.E. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res., 2007, 313(10), 2050-2062.
[http://dx.doi.org/10.1016/j.yexcr.2007.03.040] [PMID: 17512929]
[15]
Kim, E.S.; Jeong, C.S.; Moon, A. Genipin, a constituent of Gardenia jasminoides Ellis, induces apoptosis and inhibits invasion in MDA-MB-231 breast cancer cells. Oncol. Rep., 2012, 27(2), 567-572.
[http://dx.doi.org/10.3892/or.2011.1508] [PMID: 22020372]
[16]
Cheng, G.; Fan, X.; Hao, M.; Wang, J.; Zhou, X.; Sun, X. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Mol. Cancer, 2016, 15(1), 30.
[http://dx.doi.org/10.1186/s12943-016-0515-5] [PMID: 27130446]
[17]
Nalluri, S.; Ghoshal-Gupta, S.; Kutiyanawalla, A.; Gayatri, S.; Lee, B.R.; Jiwani, S.; Rojiani, A.M.; Rojiani, M.V. TIMP-1 inhibits apoptosis in lung adenocarcinoma cells via interaction with Bcl-2. PLoS One, 2015, 10(9)e0137673
[http://dx.doi.org/10.1371/journal.pone.0137673] [PMID: 26366732]
[18]
Lee, S.J.; Yoo, H.J.; Bae, Y.S.; Kim, H.J.; Lee, S.T. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem. Biophys. Res. Commun., 2003, 312(4), 1196-1201.
[http://dx.doi.org/10.1016/j.bbrc.2003.11.050] [PMID: 14652000]
[19]
Lai, C-Y.; Chang, W-S.; Hsieh, Y-H.; Hsu, C-M.; Tsai, C-W.; Chen, A-C.; Wang, C-H.; Bau, D-T. Association of tissue inhibitor of metalloproteinase-1 genotypes with lung cancer risk in taiwan. Anticancer Res., 2016, 36(1), 155-160.
[PMID: 26722039]
[20]
Michael, M.; Babic, B.; Khokha, R.; Tsao, M.; Ho, J.; Pintilie, M.; Leco, K.; Chamberlain, D.; Shepherd, F.A. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol., 1999, 17(6), 1802-1808.
[http://dx.doi.org/10.1200/JCO.1999.17.6.1802] [PMID: 10561218]
[21]
Liang, J.; Lin, M.; Xie, M.; Liu, X. [Expressions of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 and their correlation with metastasis and prognosis in lung cancer] Zhongguo Fei Ai Za Zhi, 2003, 6(1), 46-50.
[http://dx.doi.org/10.3779/j.issn.1009-3419.2003.01.12] [PMID: 21262148]
[22]
Suemitsu, R.; Yoshino, I.; Tomiyasu, M.; Fukuyama, S.; Okamoto, T.; Maehara, Y. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg. Today, 2004, 34(11), 896-901.
[http://dx.doi.org/10.1007/s00595-004-2853-y] [PMID: 15526122]
[23]
Zhu, Z.H.; Sun, B.Y.; Ma, Y.; Shao, J.Y.; Long, H.; Zhang, X.; Fu, J.H.; Zhang, L.J.; Su, X.D.; Wu, Q.L.; Ling, P.; Chen, M.; Xie, Z.M.; Hu, Y.; Rong, T.H. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J. Clin. Oncol., 2009, 27(7), 1091-1099.
[http://dx.doi.org/10.1200/JCO.2008.16.6991] [PMID: 19188679]
[24]
Pesta, M.; Kulda, V.; Kucera, R.; Pesek, M.; Vrzalova, J.; Liska, V.; Pecen, L.; Treska, V.; Safranek, J.; Prazakova, M.; Vycital, O.; Bruha, J.; Holubec, L.; Topolcan, O. Prognostic significance of TIMP-1 in non-small cell lung cancer. Anticancer Res., 2011, 31(11), 4031-4038.
[PMID: 22110238]
[25]
Gumustekin, M.; Kargi, A.; Bulut, G.; Gozukizil, A.; Ulukus, C.; Oztop, I.; Atabey, N. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol. Oncol. Res., 2012, 18(2), 209-218.
[http://dx.doi.org/10.1007/s12253-011-9430-7] [PMID: 21779788]
[26]
Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev., 2015, 4(1), 1.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[27]
Wells, G.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in metaanalyses. 2013, Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed Date: November 02, 2017)
[28]
Higgins, J.P.T.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.handbook.cochrane.org
[29]
Zein, H. Tran, V.; Abdelmotaleb Ghazy, A.; Mohammed, A.T.; Ahmed, A.; Iraqi, A.; Nguyen, H. How to extract data from graphs using plot digitizer or getdata graph digitizer. Tech. Rep., 2015, pp. 1-13.
[30]
Aljada, I.S.; Ramnath, N.; Donohue, K.; Harvey, S.; Brooks, J.J.; Wiseman, S.M.; Khoury, T.; Loewen, G.; Slocum, H.K.; Anderson, T.M.; Bepler, G.; Tan, D. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol., 2004, 22(16), 3218-3229.
[http://dx.doi.org/10.1200/JCO.2004.02.110] [PMID: 15249585]
[31]
An, H.J.; Lee, Y-J.; Hong, S.A.; Kim, J-O.; Lee, K.Y.; Kim, Y.K.; Park, J.K.; Kang, J-H. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol. Res. Pract., 2016, 212(5), 357-364.
[http://dx.doi.org/ 10.1016/j.prp.2015.11.014] [PMID: 26995105]
[32]
Blumenschein, G.R., Jr; Reck, M.; Fossella, F.; Stewart, D.J.; Lathia, C.; Peña, C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark., 2011-2012, 10(6), 287-298.
[http://dx.doi.org/10.3233/CBM-2012-0253] [PMID: 22820084]
[33]
Gouyer, V.; Conti, M.; Devos, P.; Zerimech, F.; Copin, M.C.; Créme, E.; Wurtz, A.; Porte, H.; Huet, G. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer, 2005, 103(8), 1676-1684.
[http://dx.doi.org/10.1002/cncr.20965] [PMID: 15754326]
[34]
Hoikkala, S.; Pääkkö, P.; Soini, Y.; Mäkitaro, R.; Kinnula, V.; Turpeenniemi-Hujanen, T. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett., 2006, 236(1), 125-132.
[http://dx.doi.org/10.1016/j.canlet.2005.05.012] [PMID: 15982804]
[35]
Iniesta, P.; Morán, A.; De Juan, C.; Gómez, A.; Hernando, F.; García-Aranda, C.; Frías, C.; Díaz-López, A.; Rodríguez-Jiménez, F.J.; Balibrea, J.L.; Benito, M. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol. Rep., 2007, 17(1), 217-223.
[http://dx.doi.org/10.3892/or.17.1.217] [PMID: 17143501]
[36]
Lou, E.; Johnson, M.; Sima, C.; Gonzalez-Espinoza, R.; Fleisher, M.; Kris, M.G.; Azzoli, C.G. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. Cancer Biomark., 2014, 14(4), 207-214.
[http://dx.doi.org/10.3233/CBM-140399] [PMID: 24934363]
[37]
Simi, L.; Andreani, M.; Davini, F.; Janni, A.; Pazzagli, M.; Serio, M.; Orlando, C. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer, 2004, 45(2), 171-179.
[http://dx.doi.org/10.1016/j.lungcan.2004.01.014] [PMID: 15246188]
[38]
Ylisirniö, S.; Höyhtyä, M.; Mäkitaro, R.; Pääakkö, P.; Risteli, J.; Kinnula, V.L.; Turpeenniemi-Hujanen, T.; Jukkola, A. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin. Cancer Res., 2001, 7(6), 1633-1637.
[PMID: 11410500]
[39]
Cao, J.W.; Liud, S.; Panh, H. Expressions of MMP-9 and TIMP-1 in non-small cell lung cancer and the relations to Metastasis and prognosis. Chin. J. Oncol. Prev. Treat., 2010, 2(3), 179-182.
[40]
Chen, G.Q.; Gu, Y.; Liu, F. The expression and signif-icance of immunohistochemical indexesin the prognosis of non-small cell lung cancer patients. China Trop. Med., 2006, 6(10), 1755-1757.
[41]
Fong, K.M.; Kida, Y.; Zimmerman, P.V.; Smith, P.J. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res., 1996, 2(8), 1369-1372.
[PMID: 9816309]
[42]
Han, Q.; Kong, N.; Wu, G. Expression and clinical signifi-cance of vascular endothelial growth factor, matrix metallo-proteinase-9 and tissue inhibitor of metalloproteinase in non-small cell lung cancer. China Med. Frontier J., 2015, 7(5), 109-111.
[43]
He, B.; Li, L.; Wu, D. Expression of MMP-9 and TIMP-1 in non-small cell lung carcinoma. Shaanxi Med. J., 2007, 36(9), 1232-1235.
[44]
Jiang, X.; Meng, Q.; Chen, D.; Fan, H.; Gu, Li. Expression of MMP-9 and TIMP-1 in non-small cell lung cancer and their clinical value. Med. J. Chin. People' s Armed Police Forces., 2002, 13(02), 67.
[45]
Kim, R.H.; Yang, S.H.; Jeong, E.T. The relationship between expression of matrix metalloproteinase (MMPs)-2,9 and Tis-sue inhibitors of metalloproteinase (TIMPs) - 1, 2 and sur-vival time in resected non-small cell lung cancer. Tuberc. Respir. Dis. (Seoul), 2002, 52(5), 453-462.
[http://dx.doi.org/10.4046/trd.2002.52.5.453]
[46]
Kumaki, F.; Matsui, K.; Kawai, T.; Ozeki, Y.; Yu, Z.X.; Ferrans, V.J.; Travis, W.D. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am. J. Pathol., 2001, 159(6), 2125-2135.
[http://dx.doi.org/10.1016/S0002-9440(10)63064-7] [PMID: 11733363]
[47]
Li, Q.; Wang, Y.; Xie, C.; Qiu, X.; Wang, E. Expression of MMP-2, MMP-9, TIMP-1 in non-small cell lung cancer and its relationship with prognosis. Chin. J. Lung Cancer., 2004, 7(6), 497-500.
[PMID: 21251406]
[48]
Li, J.; Liu, A.; Chen, B. Expression and clinical significance of S100A 4, MMP 9 and TIMP 1 in non-small cell lung cancer. Shaanxi Med. J., 2007, 9(36), 1149-1152.
[49]
Liang, N.; Wan, X. Correlation between expression of MMP-9, TIMP-1 and VEGF and the invasion of non small cell lung cancer. J. Kunming Med. Univ., 2016, 37(10), 67-70.
[50]
Lim, B.J.; Jung, S.S.; Choi, S.Y.; Lee, C.S. Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol. Med. Rep., 2010, 3(1), 43-49.
[http://dx.doi.org/ 10.3892/mmr_00000216] [PMID: 21472198]
[51]
Nawrocki, B.; Polette, M.; Marchand, V.; Monteau, M.; Gillery, P.; Tournier, J.M.; Birembaut, P. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int. J. Cancer, 1997, 72(4), 556-564.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19970807)72:4<556:AID-IJC2>3.0.CO;2-P] [PMID: 9259391]
[52]
Nie, C.; Xie, H.; Ke, H.; Zhou, Z. The relationship between TIMP-1 and MMP-9 and the prognosis of patients with non-small cell lung cancer. J. Clin. Med., 2017, 4(89), 17438-17439.
[53]
Rui, J.; Cuihuan, W.; Shiying, Y. Expression of MMP-13 And TIMP-1 and their correlation with prognosis in nonsmall cell lung cancer. Chinese J. Histochem. Cytochem, 2008, 2, 00.
[54]
Tang, C.; Luo, D.; Yang, H.; Wang, Q.; Zhang, R.; Liu, G.; Zhou, X. Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases. Appl. Immunohistochem. Mol. Morphol., 2013, 21(5), 386-394.
[http://dx.doi.org/10.1097/PAI.0b013e31827da3f9] [PMID: 23343958]
[55]
Thomas, P.; Khokha, R.; Shepherd, F.A.; Feld, R.; Tsao, M.S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol., 2000, 190(2), 150-156.
[http://dx.doi.org/10.1002/(SICI)1096-9896(200002)190:2<150:AID-PATH510>3.0.CO;2-W] [PMID: 10657012]
[56]
Wang, W.; Chen, S.; Wen, J.; Xiao, G.; Zhou, S. Expression and metastasis prognosis of CD44V6 MMP2, MMP9, TIMP1 and TIMP2 in non- small cell lung cancer. China Med. Engg., 2007, 15(2), 122-130.
[57]
Wills, B.; Cardona, A.F.; Rojas, L.; Ruiz-Patiño, A.; Arrieta, O.; Reguart, N.; Carranza, H.; Vargas, C.; Otero, J.; Corrales, L.; Martín, C.; Cuello, M.; Pino, L.E.; Rolfo, C.; Rosell, R.; Zatarain-Barrón, Z.L. Latin-american consortium for the investigation of lung cancer (CLICaP). Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab. Anticancer Res., 2017, 37(11), 6429-6436.
[PMID: 29061829]
[58]
Xu, H.; Chen, X.; Huang, D.; Huang, X.; Wang, D.; Huo, Q. Expression and significance of MMP-9 and TIMP-1 in Non-small cell lung cancer. J. Clin. Exp. Pathol., 2011, 27(10), 1084-1086.
[http://dx.doi.org/10.21037/tcr.2017.12.18]
[59]
Yang, B.; Sheng, H.; Yuan, C. Expression of MMP-9 and its inhibitor TIMP-1 in non-small cell lung cancer and its correlation with pathological features. Chin J. Lab. Diagn., 2009, 13(9), 1166-1167.
[60]
Zhou, J.; Wang, W.; Wen, J. Clinicopathological significance of MMP2, MMP9, TIMP1 and TIMP2 expressions in human non-small cell lung cancer. Pract. Prev. Med., 2006, 13(1), 23-26.
[61]
Zhu, B.; Zhao, H.; Wang, Y.; Lao, M.; Huang, Z.; Liu, Z.; Xie, J.; Ou, C. Research on the expressions of KAI1 gene, TIMP-1 and MMP-9 and their correlations with clinico-pathologic features of non-small cell lung cancer. Lab. Med., 2014, 29(3), 279-282.
[62]
Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, 21(11), 1539-1558.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[63]
Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109), 629-634.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[64]
Duval, S.; Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 2000, 56(2), 455-463.
[http://dx.doi.org/10.1111/j.0006-341X.2000.00455.x] [PMID: 10877304]
[65]
Zhong, A. Expression of MMP-2 and TIMP-1 and the corre-lation with clinical stages and metastasis in lung carcinoma patients. J. North China Coal Med. College, 2007, 9(5), 305-307.
[66]
Jiang, Y.; Goldberg, I.D.; Shi, Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene, 2002, 21(14), 2245-2252.
[http://dx.doi.org/10.1038/sj.onc.1205291] [PMID: 11948407]
[67]
Lempinen, M.; Lyytinen, I.; Nordin, A.; Tervahartiala, T.; Mäkisalo, H.; Sorsa, T.; Isoniemi, H. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Ann. Med., 2013, 45(7), 482-487.
[http://dx.doi.org/10.3109/07853890.2013.823779] [PMID: 23962148]
[68]
Tsagaraki, I.; Tsilibary, E.C.; Tzinia, A.K. TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis. Cell Tissue Res., 2010, 342(1), 87-96.
[http://dx.doi.org/10.1007/s00441-010-1025-1] [PMID: 20798956]
[69]
Roy, R.; Zurakowski, D.; Wischhusen, J.; Frauenhoffer, C.; Hooshmand, S.; Kulke, M.; Moses, M.A. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br. J. Cancer, 2014, 111(9), 1772-1779.
[http://dx.doi.org/10.1038/bjc.2014.462] [PMID: 25137018]
[70]
Bodnar, M.; Szylberg, Ł.; Kazmierczak, W.; Marszalek, A. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors. J. Oral Pathol. Med., 2015, 44(6), 437-443.
[http://dx.doi.org/10.1111/jop.12270] [PMID: 25244188]
[71]
Cui, H.; Seubert, B.; Stahl, E.; Dietz, H.; Reuning, U.; Moreno-Leon, L.; Ilie, M.; Hofman, P.; Nagase, H.; Mari, B.; Krüger, A. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene, 2015, 34(28), 3640-3650.
[http://dx.doi.org/10.1038/onc.2014.300] [PMID: 25263437]
[72]
Song, T.; Dou, C.; Jia, Y.; Tu, K.; Zheng, X. TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget, 2015, 6(14), 12061-12079.
[http://dx.doi.org/10.18632/oncotarget.3616] [PMID: 25909286]
[73]
Ikenaka, Y.; Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Noguchi, R.; Tsujinoue, H.; Yanase, K.; Namisaki, T.; Imazu, H.; Masaki, T.; Fukui, H. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int. J. Cancer, 2003, 105(3), 340-346.
[http://dx.doi.org/10.1002/ijc.11094] [PMID: 12704667]
[74]
Liao, C.; Yu, Z.; Guo, W.; Liu, Q.; Wu, Y.; Li, Y.; Bai, L. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark., 2014, 14(6), 469-481.
[http://dx.doi.org/10.3233/CBM-140423] [PMID: 25335739]
[75]
Zheng, C.L.; Qiu, C.; Shen, M.X.; Qu, X.; Zhang, T.H.; Zhang, J.H.; Du, J.J. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis. Asian Pac. J. Cancer Prev., 2015, 16(5), 1881-1895.
[http://dx.doi.org/10.7314/APJCP.2015.16.5.1881] [PMID: 25773840]
[76]
Gong, L.; Wu, D.; Zou, J.; Chen, J.; Chen, L.; Chen, Y.; Ni, C.; Yuan, H. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 2016, 7(14), 18458-18468.
[http://dx.doi.org/10.18632/oncotarget.7607] [PMID: 26918342]
[77]
Wang, X.F.; Zhu, Y.T.; Wang, J.J.; Zeng, D.X.; Mu, C.Y.; Chen, Y.B.; Lei, W.; Zhu, Y.H.; Huang, J.A. The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients. PLoS One, 2017, 12(9)e0185168
[http://dx.doi.org/10.1371/journal.pone.0185168] [PMID: 28934305]
[78]
Alevizakos, M.; Kaltsas, S.; Syrigos, K.N. The VEGF pathway in lung cancer. Cancer Chemother. Pharmacol., 2013, 72(6), 1169-1181.
[http://dx.doi.org/10.1007/s00280-013-2298-3] [PMID: 24085262]
[79]
Guo, Y.; Xu, F.; Lu, T.; Duan, Z.; Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev., 2012, 38(7), 904-910.
[http://dx.doi.org/10.1016/j.ctrv.2012.04.007] [PMID: 22651903]
[80]
Pan, B.; Shen, J.; Cao, J.; Zhou, Y.; Shang, L.; Jin, S.; Cao, S.; Che, D.; Liu, F.; Yu, Y. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci. Rep., 2015, 5, 16053.
[http://dx.doi.org/10.1038/srep16053] [PMID: 26524953]
[81]
Jung, K.K.; Liu, X.W.; Chirco, R.; Fridman, R.; Kim, H.R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J., 2006, 25(17), 3934-3942.
[http://dx.doi.org/10.1038/sj.emboj.7601281] [PMID: 16917503]
[82]
Toricelli, M.; Melo, F.H.; Peres, G.B.; Silva, D.C.; Jasiulionis, M.G. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol. Cancer, 2013, 12, 22.
[http://dx.doi.org/10.1186/1476-4598-12-22] [PMID: 23522389]
[83]
Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8, 16.
[http://dx.doi.org/10.1186/1745-6215-8-16] [PMID: 17555582]
[84]
Langfort, R. The new recommendation of the seventh edition of TNM classification for Lung Cancer in pathologic as-sesssment (pTNM).Adv. Respir. Med; , 2010, 78, pp. (6)379-383.
[PMID: 21077028]
[85]
Langfort, R. The new recommendation of the 7th edition of TNM classification for Lung Cancer in pathologic assesssment (pTNM).Adv. Respir. Med; , 2010, 78, pp. (6)379-383.
[PMID: 21077028]

Rights & Permissions Print Cite
Article Metrics
21
3
© 2024 Bentham Science Publishers | Privacy Policy